Zetagen Therapeutics, a privately held clinical-stage biopharmaceutical company pioneering first-of-its-kind targeted therapies for both primary and metastatic breast cancer, announced today that its ...
SYRACUSE, N.Y.--(BUSINESS WIRE)--Central New York Biotech Accelerator (CNYBAC) — Zetagen Therapeutics, Inc., a private, clinical stage, biopharmaceutical company focused on developing breakthrough ...
Case study demonstrated resolution of lytic lesions, significant reduction in pain and prevention of fracture. ZetaMet™ is a first-of-its kind molecular pathway designed to suspend cancer, inhibit ...
Metastasis Stage, Adjuvant Treatment, and Residual Tumor Are Prognostic Factors for Medulloblastoma in Children: Conclusions From the Children's Cancer Group 921 Randomized Phase III Study PURPOSE: To ...
MedPage Today on MSN
How to Treat Multiple Myeloma Patients With Renal Impairment
In patients with symptomatic multiple myeloma, renal impairment leading to acute kidney injury (AKI) is a common complication ...
RECIST was developed in 2000 by the National Cancer Institute, European Organization for Research and Treatment of Cancer, and National Cancer Institute of Canada, with revision to RECIST 1.1 in 2009 ...
For most people living with multiple myeloma, bone pain tops the list of symptoms. No wonder, given that the disease causes cancerous plasma cells to build up in bone marrow (the soft tissue in bones) ...
A study suggests a new approach, or, possibly two new approaches against prostate cancer bone metastases: While targeted therapies and anti-cancer immunotherapies have not been especially successful ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback